While children receiving chemotherapy routinely undergo hearing tests, adults don’t, and a new study by UC San Francisco (UCSF) reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer. The researchers found that more than half the survivors in their study who had been treated with chemotherapy experienced significant hearing problems.
In a new study published in the journal “Development,” USC Stem Cell scientists describe how adult flies can regenerate sensory hearing cells in their antennae, and how studying flies can provide a new way to understand and develop treatments for the hundreds of millions of patients worldwide who live with hearing and balance disorders.
According to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.
“Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss, and otoprotection,” said Kathie Bishop, PhD, chief scientific officer of Otonomy.
Read More
UConn otolaryngologist Kourosh Parham and his colleagues report in “Hearing Research” that levels of prestin, a protein found only in cells in the inner ear, rise sharply when those cells are damaged and start to die.
Read More
Since 2016, the Ida Institute Research Committee has awarded research grants to projects that investigate the outcomes of using Ida Institute methods and tools and develop evidence to show the effect of person-centered hearing care.
Read More
This half-day event follows the Food and Drug Administration’s (FDA) model for externally-led Patient Focused Drug Development meetings and serves to inform the agency’s regulatory decision-making in pediatric oncology.
Read More
The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the US, Canada, Israel, and Turkey, and enroll approximately 260 patients.
Read More
The study showed that STS administered six hours after Cisplatin could reduce the severity of hearing loss without affecting the chance of cure for the cancer.
Read More
According to the FDA, Breakthrough Therapy designation is given when preliminary clinical evidence has been provided to show that a treatment effect may represent substantial improvement over available therapies for the treatment of a serious condition.
Read More
Using a new technique to deliver steroids to the inner ear, developed with funding from Action on Hearing Loss, Otomagnetics has been able to reduce hearing loss in mice treated with the chemotherapy drug cisplatin by 50%.
Read More
The drug is a therapy in development for the treatment of hearing disorders, for the prevention of Platinum-Induced Ototoxicity in pediatric patients.
Read More
Sound Pharmaceuticals announced that the company has been awarded up to $1.6 million for their development of a drug used to treat ototoxicity in patients with cystic fibrosis.
Read More
Otonomy has announced the enrollment of the first patients in a Phase 2 clinical trial evaluating OTO-104 for the prevention of hearing loss in cancer patients undergoing chemotherapy with platinum-based agents.
Read MoreSiemens Hearing Instruments, Inc. has announced partnerships with the Pediatric Brain Tumor Foundation (PBTF) and CancerCare® to bring top-of-the-line hearing aids and audiology services to cancer patients across the country.
Read More